

99 學年第一學期 專題討論-生物科技管理實務

Organizer : 陽明大學新藥研究中心吳榮燦主任
政治大學科技管理研究所吳豐祥所長

列席老師 : 政治大學智慧財產所馮震宇所長
陽明大學蘇瑀所長
政治大學陳桂恆教授 (前美國 FDA 學名藥部門主管)
惇安法律事務所王惠玲顧問
台灣經濟研究院生物科技產業研究中心暨智慧財產評價服務中心
孫智麗主任
技術經理人協會蔡熙文秘書長
陽明大學林敬哲教授

時間 : pm 6:30 ~ 9:30

地點 : 陽明大學/傳統醫學大樓乙棟一樓 階梯教室 政治大學/商學院 R914

標示 * 者, 報告時間總長為 50 分鐘: 30 分鐘講者報告/ 20 分鐘討論

未標示 * 者, 報告時間總長為 40 分鐘: 20 分鐘講者報告/ 20 分鐘討論

| Date | Topic | Speaker | Adviser |
|-------------|--|---------|--|
| 10/14 政大 | In re Gleave: novelty, 560 F.3d 1331 (Fed. Cir. 2009) | 王華勇* | 吳榮燦 馮震宇 吳豐祥 陳桂恆 王惠玲 孫智麗 蔡熙文 |
| | Empirical analysis of major stem cell patent cases: the role of universities-Nature Biotechnology 28325, 2010 | 陳映如 | |
| | In re Kubin: non-obviousness, 561 F.3d 1351 (Fed. Cir. 2009) | 張濱璿* | |
| | The obviousness rejection as a barrier to biotech patent prosecution-Nature Biotechnology 27:1125, 2009 | 陳宛渝 | |
| 10/28 陽明 | In re Ciprofloxacin Antitrust Litigation. (2d Cir. 2010) | 鄭亦珊* | 吳榮燦 馮震宇 吳豐祥 陳桂恆 王惠玲 孫智麗 蔡熙文 林敬哲 |
| | Disclosing discoveries- Nature Biotechnology 28:892, 2010 | 張駿義 | |
| | <i>Bilski v. Kappos</i> : the US Supreme Court broadens patent subject-matter eligibility <i>Nature Biotechnology</i> 28:801, 2010 | 劉依蓁* | |
| | Virtual drug discovery with the rise of Chinese CROs-Drug Discovery Today 15:693, 2010 | 鐘婉平 | |
| 11/11 政大 | Will the patentability of genes survive? Nature Biotechnology 28:925, 2010 | 譚詣騰* | 吳榮燦 馮震宇 |

| | | | |
|-------------|---|------|--|
| | Medicines discovery in the 21st century: the case for a stakeholder corporation-Drug Discovery Today 15:700, 2010 | 薛曼君 | 吳豐祥 陳桂恆 王惠玲 孫智麗 蔡熙文 |
| | Merck loses Temodar patent Nature Reviews Drug Discovery 9:184, 2010 | 鄭羽琇* | |
| | Does R&D pay? Drug Discovery Today 15:230, 2010 | 高于婷 | |
| 11/25 陽明 | Sun Pharmaceuticals wins Gemzar patent dispute Nature Reviews Drug Discovery 9:672, 2010 | 謝文馨* | 吳榮燦 馮震宇 吳豐祥 陳桂恆 王惠玲 孫智麗 蔡熙文 林敬哲 |
| | The challenges of product development and commercialization in a convergence technology world- focus on regenerative medicine Drug Discovery Today 15:587, 2010 | 蔡怡萱 | |
| | Controversial NF-κB patent falls down on written description- Nature Reviews Drug Discovery 9:352, 2010 | 許志堅* | |
| | The Drug Discovery Portal: a resource to enhance drug discovery from academia Drug Discovery Today 15:679, 2010 | 張文瀚 | |
| 12/9 政大 | US Patent Office overturns stem cell patent Nature Reviews Drug Discovery 9:424, 2010 | 許鈺佳* | 吳榮燦 馮震宇 吳豐祥 陳桂恆 王惠玲 孫智麗 蔡熙文 |
| | The strategy of enantiomer patents of drugs Drug Discovery Today 15:163, 2010 | 莊友均 | |
| | Dosage regimens are patentable Nature Reviews Drug Discovery 9:262, 2010 | 周芳君* | |
| | The case for entrepreneurship in R&D in the pharmaceutical industry Nature Reviews Drug Discovery 9:683, 2010 | 戴瑜廷 | |
| 12/23 陽明 | Goeddel v. Sugano: Written Description- Description must do more than allow PHOSITA to “Envision” the claimed invention (Fed. Cir. 2010) | 林穎正* | 吳榮燦 馮震宇 吳豐祥 陳桂恆 王惠玲 孫智麗 蔡熙文 |
| | Changing the rules of the game: addressing the conflict between free access to scientific discovery and intellectual property rights Nature Biotechnology 28:137, 2010 | 林彥伶 | |
| | King Pharmaceuticals, Inc. v. Eon Labs, Inc.: Inherent Anticipation and Inherent Obviousness? (Fed. Cir. 2010) | 胡栢睿* | |
| | The importance of foreign-born talent for US innovation Nature Biotechnology 28:289, 2010 | 汪佩妮 | |
| 1/6 政大 | Drug discovery: new models for industry-academic partnerships • Review article-Drug Discovery Today 14:95, 2009 | 張容華 | 吳榮燦 馮震宇 |

| | | | |
|------------|--|-----|---|
| | Terminal disclaimers and obviousness-type double patenting Nature Reviews Drug Discovery 9:184, 2010 | 黃瀨瑩 | 吳豐祥 陳桂恆 王惠玲 孫智麗 蔡熙文 |
| | Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years Nature Reviews Drug Discovery 9:519, 2010 | 莊凱嶠 | |
| | Pluripotent patents make prime time- an analysis of the emerging landscape Nature Biotechnology 28:557, 2010 | 謝宗翰 | |
| 1/20 陽明 | Assessing the bioequivalence of biosimilars Drug Discovery Today 14:495, 2009 | 王誌慶 | 吳榮燦 馮震宇 吳豐祥 陳桂恆 王惠玲 孫智麗 蔡熙文 |
| | Diagnostics firms face new patent claim worries Nature Biotechnology 27:586, 2009 | 羅邵晏 | |
| | Pfizer stakes a claim in plant cell-made biopharmaceuticals | 何安婷 | |